Altered Homeostasis of CD4+ Memory T Cells in Allogeneic Hematopoietic Stem Cell Transplant Recipients: Chronic Graft-versus-Host Disease Enhances T Cell Differentiation and Exhausts Central Memory T Cell Pool

Department of Hematology and Oncology, Kyoto University, Kioto, Kyōto, Japan
Biology of Blood and Marrow Transplantation (Impact Factor: 3.4). 11/2007; 13(10):1176-84. DOI: 10.1016/j.bbmt.2007.06.009
Source: PubMed


An increased risk of late infection is a serious complication after allogeneic hematopoietic stem cell transplantation (AHSCT), especially for recipients with defective CD4(+) T cell recovery. Although chronic graft-versus-host disease (cGVHD) negatively influences CD4(+) T cell reconstitution, the mechanisms leading to this defect are not well understood. We found that the proportion of CD27(-) CD4(+) T cells was remarkably increased in ASHCT recipients with cGVHD or with repetitive infectious episodes. Isolated CD27(-) CD4(+) T cells from ASHCT recipients had significantly shortened telomere length, displayed enhanced vulnerability to activation-induced cell death, and showed extremely reduced clonal diversity, when compared with CD27(-) CD4(+) T cells from healthy donors. Also, CD27(+) CD4(+) T cells from AHSCT recipients easily lost their expression of CD27 in response to antigen stimulation regardless of cGVHD status. Taken together, these data indicate that homeostasis of memory CD4(+) T cells from AHSCT recipients is altered, and that they easily transit into CD27(-) effector memory T cells. Increased in vivo T cell stimulation observed in recipients with cGVHD further promotes the transition to effector memory cells, a change that decreases the central memory CD4(+) T cell pool and consequently weakens the recipient's defense against persistently infecting pathogens.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Eighteen patients undergoing allogeneic hematopoitic stem cell transplantation (allo-HSCT) at the Zhongshan Hospital, Sun Yat-sen University from January 2004 to January 2007, were enrolled. There were 8 cases of identical HLA sibling donor, 9 cases of HLA sibling donor except A/B/DR site, and 1 case of unrelated identical HLA donor. According to different conditions of donor-recipient HLA compatibility, strategies for prophylaxis of acute Graft-versus-host disease (GVHD) were made and based on combination of low-dose cyclosporine-A (CSA) and short course methotrexate (MTX). Methylprednisolone (MP) was used as primary therapy for acute GVHD, and other immunosuppressants were administered to those who fail to respond to MP as secondary or salvage therapy. Therapy for chronic GVHD included prednisone and CSA. All 18 patients were successfully engrafted. Acute GVHD occurred in 12 of 18 patients (66.7%). Six cases had never developed GVHD. The incidence of Grade II-IV acute GVHD were 11.1% and 55.6% among HLA-A, B, DR identical and mismatched HSCT patients respectively. Chronic GVHD were observed in 7 of 18 patients (38.9%). Of 12 recipients with acute GVHD, 10 achieved clinical response after treatment, and two had no response and died. Of 7 recipients with chronic GVHD, 6 achieved clinical response after treatment and one had no response and died. None of patients had tumor relapsed. GVHD could be controlled relatively efficiently by adopting different methods for prevention and treatment according to HLA-matching.
    No preview · Article · Nov 2008 · Journal of Clinical Rehabilitative Tissue Engineering Research
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Allogeneic stem cell transplantation has become standard therapy for hematologic malignancies through the positive immunologic graft-versus-leukemia effect. Initial immune recovery relies on peripheral expansion of infused T cells, which switch to a memory-like phenotype. This study prospectively investigated whether changes in subset composition precedes complications after myeloablative HLA-matched transplantation for hematologic malignancies. Of 80 allograft recipients, 18 were still free of clinical complication throughout 395 to 1564 days of follow-up. Compared with this complication-free subgroup, patients who developed chronic graft-versus-host disease (cGVHD) without relapsing recovered similar numbers of circulating T cells with predominance of CD8+ T cells lacking CC-chemokine receptor-7 and CD28 expression throughout the first year after transplantation. Conversely, poor CD8+ T cell recovery with diminished numbers of CD28neg CD8+ T cells (approximately 1/4th of that of relapse-free patients) preceded occurrence of malignant relapse. In multivariate analysis, lower CD28neg CD8+ T cell counts by day 60 postallograft were associated with a greater risk of subsequent relapse (hazard ratio [HR] 0.33; 95% confidence interval [CI]: 0.14-0.76; P = .01). Enumeration of CD28neg CD8+ T cells in patients could assist in predicting risk of relapse and help build an algorithm for accelerating the immune recovery by reducing the immunosuppressive treatment and considering the introduction of preemptive donor lymphocyte infusions.
    Preview · Article · May 2009 · Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation
  • [Show abstract] [Hide abstract]
    ABSTRACT: CD4 T cells play a significant role in the pathogenesis of rejection, providing help to alloreactive CD8 and B cells, however, the exact contribution of each memory compartment in vivo has not been defined. They are also important for the maintenance of tolerance due to regulatory activity of specialized subsets. In this study, we assessed changes in frequencies of functionally distinct lymphocyte subsets of peripheral blood (PBLs) in 26 heart transplant recipients (HT) in association with rejection episodes. Patients who developed rejection (n = 7), namely Grade 3B (n = 1), 3A (n = 4), or 2 (n = 2), in comparison with those with stable graft function displayed at baseline (pre-HT) higher percentages of naive (CCR7+CD45RA+) CD4 T cells (median 48 vs 36.6%; P = .035) and lower percentages of central memory (CCR7+CD45RA-) CD4 T cells (33.3 vs 46.5%; P = .035). At 30 days post-HT, CD4/CD127(low)FoxP3+ T cells were significantly reduced among patients with rejection episodes (0.84 vs 2.15%; P = .042). CD8 final effector T cells were increased at 90 days post-HT among those patients who experienced rejection (TEM2: 60.8 vs 31.9%; P < .1), at the expense of shrinking CD8 central memory compartment (TCM: 8.6 vs 12.9%; P = .046). The potential role of T-cell memory distribution should be further evaluated in HT patients as possible markers to discriminate patients at risk for rejection.
    No preview · Article · Jul 2009 · Transplantation Proceedings
Show more